ArticlesMedicine Compliance Aid StabilityLactation Safety InformationNew Medicines ·


Medicine Compliance Aid Stability

ZofranGlaxoSmithKline UK

GlaxoSmithKline UK
Tablets f/c 4mg, 8mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from light and store in airtight containers.
21 January 2015

Zofran MeltGlaxoSmithKline UK

GlaxoSmithKline UK
Zofran Melt
Oral lyophilisates 4mg, 8mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Tablet designed to dissolve on tongue - unsuitable for MCA
21 January 2015

Lactation Safety Information

Alternative anti-emetic if appropriate
5HT3-receptor antagonist
No published evidence of safety
Used in infants > 1 month
15 July 2019

New Medicines

BekindaGastroenteritis-associated nausea


New formulation
RedHill Biopharma
RedHill Biopharma

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials


5-HT3 antagonist - extended-release, once-daily formulation
About 20% of the UK population develop infectious intestinal disease each year. Viral infections cause 30 to 40% of gastroenteritis cases in industrialised countries. The figure is higher for children. Norovirus is the most common cause of viral infectious gastroenteritis in adults in England and Wales. Adenovirus and rotavirus are much less common in teenagers than in younger children [3].
Gastroenteritis-associated nausea